2026-07-31 02:18:39

Technology Evaluation Methodology: How We Assess Chinese Biomedical Technology

A documented methodology for evaluating Chinese biomedical technology with evidence-centered, transparent, and reproducible assessment criteria.

Evaluation Framework

Our technology evaluation methodology consists of five standardized phases:

Phase 1: Document Collection

Objective: Gather all available manufacturer and independent documentation.

  • Request technical specifications, IFU, brochures
  • Request regulatory certificates (NMPA, CE, FDA)
  • Search for independent publications
  • Collect clinical study reports

Output: Document inventory with source labeling

Phase 2: Evidence Classification

Objective: Classify each piece of evidence by source and verification status.

  • Label manufacturer-provided information
  • Assess independent verification status
  • Identify evidence gaps
  • Flag conflicting information

Output: Evidence classification matrix

Phase 3: Analytical Assessment

Objective: Assess the technology against four mandatory analytical dimensions.

  1. Local problem: What specific laboratory challenges does this technology address?
  2. Chinese solution scope: What does the Chinese manufacturer offer?
  3. Evidence boundary: What are the limits of the current evidence base?
  4. Local implementation gap: What is needed for practical implementation?

Output: Four-dimensional analytical assessment

Phase 4: Discrepancy Analysis

Objective: Identify and document any contradictions between sources.

  • Cross-reference technical specifications across documents
  • Compare manufacturer claims with independent data
  • Document all discrepancies transparently
  • Assess impact of discrepancies on clinical decisions

Output: Discrepancy report

Phase 5: Publication and Review

Objective: Publish findings with transparent labeling and schedule regular reviews.

  • Label all claims by source
  • State verification status explicitly
  • Set review schedule (annually or when new evidence emerges)
  • Publish evidence limitations

Output: Published evaluation with review schedule

Quality Standards

Reproducibility

  • All evaluations follow the same methodology
  • Evidence sources are documented for audit
  • Assessment criteria are standardized

Transparency

  • Manufacturer information is explicitly labeled
  • Evidence limitations are documented, not hidden
  • Discrepancies are published, not suppressed

Currency

  • Evaluations are reviewed annually
  • Evidence sources are checked for updates
  • Verification statuses are updated as new data emerges

Limitations

  • We do not conduct independent laboratory testing
  • We rely on manufacturer-provided documentation
  • Regulatory status is not independently verified
  • Our evaluations are not a substitute for regulatory approval